Nicola Tolliday serves as assistant director for the Broad Institute’s Therapeutics Projects Group (TPG). As part of the TPG, Tolliday works closely with experts from academia and industry to transform the process of drug discovery and the treatment of human disease by developing and applying novel drug discovery technologies; targeting novel classes of protein targets, generally viewed as “undruggable”; targeting novel mechanisms emerging from studies of human biology; and working in an open, collaborative environment to establish proofs of concept.
Before stepping into her current role, Tolliday managed the screening outreach activities at the Broad Institute for more than three years. Tolliday established the Chemical Biology Outreach Lab to support collaborators with assay development expertise, automation facilities for pilot screening, and follow-on studies for chemical biology projects within the Broad Institute discovery pipeline. Tolliday also established and led the high-throughput screening group within the Broad Institute’s Therapeutics Platform (formerly known as the Chemical Biology Platform) from 2004 to 2009.
Prior to joining the Broad Institute, Tolliday was a senior assay developer at the Harvard Institute of Chemistry and Cell Biology, where she was responsible for the development, execution, and analysis of high-throughput small-molecule screens, in particular those with relevance to cancer biology. In addition, she advised and collaborated with researchers nationwide on the design and implementation of successful high-throughput screens.
Tolliday received her B.S. from the University of Bath, England, in biochemistry, during which time she completed internships at the Weizmann Institute, Israel, and the Max Planck Institute for Biochemistry, Germany. She received her Ph.D. from Harvard University in cell biology.Last updated date: May 2013